"Designing Growth Strategies is in our DNA"
The global regenerative medicine market size was valued at USD 28.62 billion in 2022 and is projected to grow from USD 34.56 billion in 2023 to USD 197.08 billion by 2030, exhibiting a CAGR of 28.2% during the forecast period.
Regenerative medicine is an emerging field aiming to repair, replace, or regenerate damaged tissue or organ using cells, tissues, or genetic material. It can treat and potentially cure many conditions and diseases that are intractable, chronic, and terminal, such as cancers, Parkinson's disease, Alzheimer's disease, diabetes, renal diseases, cardiovascular diseases, and others. According to the Alliance for Regenerative Medicine (ARM) 2021 report, the global financing in this market was raised to USD 22.7 billion in 2021 from USD 19.9 billion in 2020 to support 2,406 products that are under investigation. This growth is attributed to the technological advancements in the gene therapy field, such as the first in-vivo CRISPR therapy which exhibited positive outcomes in 2021.
Moreover, the rising prevalence of chronic genetic disorders, coupled with increased healthcare expenditure by developed and developing countries is expected to fuel the growth of the regenerative medicine industry. For instance, in July 2022, the Washington University received a grant of USD 557,000 from the National Heart Lung and Blood Institute (NHLBI) to investigate the effectiveness of a novel engineered TRIM72 (ETRIM72) protein to regenerate vasculature and skeletal muscles in murine diabetic Critical Limb Ischemia (CLI). Such growing support from government organizations through research grants will propel the global market growth during the forecast period.
Comparatively Robust Market Performance of Cell Therapy and Gene Therapy Minimized COVID-19 Impact on Market Growth
The COVID-19 outbreak impacted the market differently as it is composed of various segments. The tissue engineering segment witnessed a significant negative decline, while the gene therapy segment witnessed robust growth due to the consistent sales of its rare disease therapeutics. Similarly, the Platelet-Rich Plasma (PRP) segment declined in 2020, whereas the cell therapy segment generated a slightly higher growth rate in 2020.
From 2022 onwards, the market is estimated to witness a consistently stronger growth rate during the forecast period. As the prevalence of chronic diseases is rising, market players are focusing on R&D initiatives to expand their pipeline candidates, which will lead to new product launches during the forecast period.
Request a Free sample to learn more about this report.
Strategic Acquisitions by Key Players to Offer Market Growth Opportunities
One of the prevailing global regenerative medicine market trends is the implementation of strategic acquisitions by key players to upscale their R&D capabilities. The products of this market comprise various novel approaches derived from living cells, proteins, enzymes, antibodies, Antibody-Drug Conjugates (ADC), and gene and cellular components that have produced life-saving therapies to treat various chronic diseases. However, there is a potential gap between expectations and the realities of translating these technologies into clinical practice. Some prominent regenerative medicine manufacturers are taking strategic initiatives to bridge this gap and expand research in various clinical applications by increasing their focus on acquisitions to strengthen their R&D capabilities.
The products of this market and cellular therapies are coming together to expand their clinical applications for the treatment of many incurable diseases and improvement of patient health outcomes.
Increasing Investments in R&D Activities Leading to Innovative Product Launches to Drive Market Growth
Increasing investments in this market have initiated full-fledged research and development activities as several investors are funding start-up companies focused on the development of novel therapies and products in the market. This has also paved the way for significant mergers, research collaborations, and partnerships to share the mutual benefits of R&D activities.
Apart from private players, various governments and government-funded research institutes are actively spending on this industry to introduce effective options for the treatment of various chronic diseases, such as cancers, Parkinson's disease, diabetes, renal diseases, cardiovascular diseases, and others.
Innovative Pipeline Candidates to Contribute to Market Growth
Regenerative medicine is broadening its application areas from tissue repair and wound care to various fields, such as cardiology, neurology, oncology, and others. Many pharmaceutical and life science companies are conducting clinical trials to establish their dominance over the traditional treatment methods by launching potential candidates that are under development, leading to the introduction of novel products and therapies in the market.
High Treatment Costs and Inadequate Reimbursement Policies to Hinder Market Growth
High costs of treatments using these products and lack of reimbursement policies are key factors restraining the market growth. For instance, most stem cell therapies are experimental or investigational drugs or treatments due to which there is limited Medicare insurance coverage leading to a considerable proportion of out-of-pocket payments. It only covers expenses of treatments that have been approved by the FDA, such as allogeneic transplantation.
Lack of coverage provided by major insurance providers leaves patients with the only option to pay the treatment cost out-of-pocket or through crowd funding, which delays the treatment and can slow the growth of the market. Moreover, there are limited approved therapies for a wide range of patients suffering from various genetic disorders, which are considerably expensive and may have other side-effects, which will restrain its adoption, limiting the market growth.
To know how our report can help streamline your business, Speak to Analyst
Cell Therapy to Gain Traction Due to Increase in Product Adoption to Treat Chronic Diseases
Based on product, the market segments includes cell therapy, gene therapy, tissue engineering, and platelet rich plasma.
The cell therapy segment dominated with the largest market share in 2022. The segment’s growth is driven by its rising applications in the treatment of autoimmune diseases, cancers, infectious diseases, musculoskeletal disorders, and repairing of joint injuries, which has increased the adoption of products of this segment.
The gene therapy segment is estimated to record the highest CAGR owing to the advantages of this therapy over traditional treatment methods including improved clinical results, targeting desirable sites, and others. Gene therapy has been widely used in the treatment of rare diseases including Spinal Muscular Atrophy (SMA) and others.
The tissue engineering segment held the second largest share in the global market due to increased demand for its products, such as scaffolds, bio matrixes, and others in wound care. On the other hand, the platelet rich plasma segment held the smallest market share in 2022 due to limited product offerings. However, the demand for cosmetic surgeries is increasing along with the gradual adoption of platelet rich plasma for the treatment of orthopedic diseases, which will propel the segment’s growth during the forecast period.
Rising Prevalence of Orthopedic Diseases to Fuel Product Adoption in Orthopedics
In terms of application, the global market is segmented into orthopedics, wound care, oncology, rare diseases, and others.
The orthopedics segment held the maximum global regenerative medicine market share in 2022 due to a gradual increase in the prevalence of osteoarthritis and bone related injuries. This has led to the adoption of these products to enhance the healing process and reduce pain and discomfort, which is driving the segment’s growth.
The oncology segment is estimated to record a comparatively higher CAGR during the forecast period. Factors, such as the rising prevalence of cancer have increased the unmet needs of cancer patients. To cater to this demand, many novel therapies have been introduced, such as CAR-T cell based therapy, which showcased significant positive results. Furthermore, increasing government support through research grants and awareness programs will contribute to the segment’s growth.
The wound care segment accounted for a considerable market value in 2022 and is estimated to register a substantial CAGR by the end of 2030. Introduction of advanced products that mimic the skin structure and accelerate wound healing, along with the rising prevalence of chronic wounds, is expected to fuel the segment’s growth.
The rare disease segment is anticipated to display the highest CAGR during the forecast period as the number of individuals living with rare diseases is rising across the world, and the treatment options are limited, providing a huge scope for the segment’s growth in the market.
The others segment comprises cardiovascular diseases, musculoskeletal, ophthalmology, and metabolic diseases where the R&D initiatives are limited and yet to be explored, which can slow the growth of the segment due to limited product launches.
Increasing Number of Surgeries to Propel Product Use across Hospitals
On the basis of end user, the global market is classified into hospitals, clinics, and others.
The hospital segment dominated with the maximum market share in 2022 and is estimated to record the highest CAGR during the forecast period. The segment’s growth is augmented due to rising number of surgeries in hospitals coupled with increasing government support through policy harmonization, which provides impetus for major companies offering these products.
The clinic segment held the second-largest market share in 2022 owing to the increased privatization of clinics to provide specialized regenerative medicine services which include treatment for musculoskeletal conditions to relieve pain and enhance the healing process. Hence, adoption of these products in these institutions is contributing to the expansion of the segment.
The others segment might showcase a lower CAGR during the forecast period. Some of the factors contributing to the segment’s slower growth rate include the stringent eligibility criteria to conduct R&D activities at academic research institutes.
North America Regenerative Medicine Market Size, 2022 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
Geographically, the global market for regenerative medicine is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America market size was valued at USD 12.77 billion in 2022 and is likely to remain dominant throughout the forecast period. The growth in this region is attributed to the technological advancements in the field, rapid adoption of cell & gene therapy, and new product approvals. For instance, in May 2022, the U.S. FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to obecabatagene autoleucel (obe-cel), a CAR T-cell therapy developed by Autolus Therapeutics and is under clinical trial for the treatment of R/R B-acute lymphocytic leukemia.
Europe is anticipated to be the second leading region in terms of revenue, which is attributed to emerging government guidelines and favorable reimbursement for these therapies. Moreover, the substantial presence of numerous research institutes and increasing government funding are expected to boost the market growth across Europe.
Asia Pacific is projected to record the maximum CAGR due to the rising prevalence of chronic diseases, active government initiatives for technological advancements, and improving disposable incomes. For instance, as per an article published in November 2021 by BioSpectrum, 8.5 million people suffered from some form of chronic disease, such as diabetes, cancer, and respiratory conditions in Asia. This rising incidence of these diseases offers a lucrative opportunity for the market to grow across the region.
On the other hand, Latin America and the Middle East & Africa regions are estimated to grow at a comparatively lower CAGR due to lower healthcare expenditure per person. Furthermore, lack of awareness regarding the existence of effective treatment options in these regions is leading to a lower adoption rate and slower growth of the regional market.
Novartis AG and Zimmer Biomet are Key Market Players due to Strong Sales Owing to New Product Launches and Approvals
In terms of the competitive landscape, the market is highly fragmented, with a few companies holding a higher proportion of the industry. In terms of cell and gene therapies, Gilead Sciences Inc. and Novartis AG are dominant players in these segments on the account of their strong CAR T-cell therapy pipeline, which is anticipated to generate strong sales due to new product launches and approvals during the forecast period. Some other emerging players that are present in cell and gene therapy segment include Orchard Therapeutics plc through its products, such as Libmeldy and Strimvelis which are approved in the European Union and bluebird bio, Inc.
In terms of tissue engineering, Stryker dominates the global market due to its acquisition of Wright Medical Group N.V., which has led to the development of a strong biologics portfolio for the company, while the platelet rich plasma segment reflects a fragmented competitive landscape. However, some key companies including Zimmer Biomet, on account of its product of GPS III Platelet Concentration System, and Terumo Corporation have established their presence in the market due to their strong product offerings.
An Infographic Representation of Regenerative Medicine Market
To get information on various segments, share your queries with us
The report provides qualitative and quantitative insights on the global market and a detailed analysis of market’s size & growth rate for all possible segments. Along with this, it provides elaborative insights on the market’s drivers and competitive landscape. Various key insights presented in the report include prevalence of chronic diseases by key countries/regions - 2021, pipeline analysis, new product launches, key recent industry developments – mergers, acquisitions, & partnerships, technological developments, and impact of COVID-19 on the global market.
CAGR of 28.2% from 2023 to 2030
Value (USD billion)
Product; Application; End User; and Region
By End User
Fortune Business Insights says that the global market size was valued at USD 28.62 billion in 2022 and is projected to reach USD 197.08 billion by 2030.
In 2022, the North America market stood at USD 12.77 billion.
Recording a CAGR of 28.2%, the market will exhibit steady growth during the forecast period of 2023-2030.
The cell therapy segment is expected to be the leading segment in this market during the forecast period.
The increasing prevalence of blood cancers and treatment initiatives for rare diseases, coupled with the rising need for personalized treatment, are some of the major factors driving the growth of the market.
Novartis AG, Stryker, and Bristol-Myers Squibb Company are the leading market players in the global market.
North America dominated the market in 2022.
The demand for cosmetic rejuvenation procedures, potential pipeline candidates, and continuous increase in R&D investment for technological advancements are expected to surge the demand for these products.
“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”- U.S.-based biotechnology company focussing on treatment of chronic pain.
“Kudos to your team. Thank you very much for your support and agility to answer our questions.”- Europe-based provider of solutions to automate data centre operations.
“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”- India-based manufacturer of industrial and specialty intermediates with a strong global presence.
“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”- One of the largest cosmetics company in the world.
“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”- U.S. based startup operating in the cultivated meat market.
“We received the below report on the U.S. market from you. We were very satisfied with the report.”- UGlobal hearing aids manufacturer.
“I just finished my first pass-through of the report. Great work! Thank you!”- U.S. based solar racking solutions provider.
“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”- World’s leading advisory firm.
“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”- Germany based machine construction company.
“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”- Japanese manufacturing company of stationery products.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry